3D pCASL在2021 WHO胶质瘤分级中的诊断价值
本回顾性单中心研究纳入530例新诊断幕上胶质肿瘤,在2021 WHO分类框架下评估3D pCASL的术前分级能力。主要分析队列511例胶质瘤中,最大肿瘤血流及相对白质、灰质归一化血流可区分2级与3-4级,AUC分别为0.848、0.833、0.84。3D pCASL无需对比剂,对2级与高级别胶质瘤及2级与3级肿瘤具有较高诊断准确性。
要点
- maxTBF阈值63.3 mL/100 g/min用于区分2级与3-4级胶质瘤。
- 无强化胶质母细胞瘤与2级星形细胞瘤可经maxTBF区分,特异度最高96%。
- 3D pCASL无需对比剂,适合术前无创胶质瘤分级评估。
核心结论
- 3D pCASL在2021 WHO框架下对2级与高级别胶质瘤及2级与3级肿瘤的区分具有较高诊断准确性。
- 3D pCASL为完全无创且无需对比剂的胶质瘤术前分级手段。
研究设计与样本
- 回顾性单中心研究,纳入2011至2024年间530例新诊断幕上胶质肿瘤患者。
- 所有患者均行3.0 T MRI及3D pCASL检查,诊断按2021 WHO框架结合组织学与分子信息重新归类,分子信息不足者归为NOS。
- 采用约30 mm²热点ROI测量最大肿瘤血流maxTBF及相对白质nTBF WM、相对灰质nTBF GM。
关键影像表现/征象
- maxTBF、nTBF WM和nTBF GM可区分2级与3-4级胶质瘤,AUC分别为0.848、0.833、0.84。
- 3D pCASL可区分无强化胶质母细胞瘤与2级星形细胞瘤,maxTBF AUC为0.78-0.86。
诊断标准与关键数值
- maxTBF区分2级与3-4级胶质瘤的阈值为63.3 mL/100 g/min。
- 2级与3级比较AUC为0.743-0.768,3级与4级比较AUC为0.668-0.715。
- 无强化胶质母细胞瘤与2级星形细胞瘤鉴别的maxTBF截断值为64.1 mL/100 g/min,特异度最高达96%。
- maxTBF与nTBF和Ki-67呈中度相关,r=0.44-0.50,pfdr<0.001。
临床应用与阅片要点
- 阅片时可对肿瘤热点区放置约30 mm² ROI测量maxTBF及nTBF,辅助2级与3-4级胶质瘤鉴别。
- 无强化病变也需结合maxTBF判断,避免将无强化胶质母细胞瘤误判为低级别星形细胞瘤。
- 排除NOS病例后,胶质母细胞瘤与4级星形细胞瘤的maxTBF及nTBF差异不显著,二者间不宜仅凭灌注参数区分。
局限性
- 回顾性单中心研究设计。
- 分子信息不全的NOS病例可能影响部分分级分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic performance of three-dimensional pseudo-continuous arterial spin labeling (3D pCASL) for preoperative grading of gliomas within the 2021 WHO classification framework and to assess protocol-specific tumor blood flow thresholds for differentiating CNS WHO grade 2 from grade 3-4 tumors.
METHODS: This retrospective single-center study included 530 patients with newly diagnosed supratentorial glial tumors examined between 2011 and 2024. Nineteen non-diffuse CNS WHO grade 1 tumors were retained for descriptive purposes only and excluded from all grading analyses; the primary analytical cohort therefore comprised 511 gliomas (grade 2, n = 75; grade 3, n = 152; grade 4, n = 284). Diagnoses were reassigned within the WHO 2021 framework using the histological and molecular information available for each patient; tumors lacking molecular information required for an integrated WHO diagnosis were designated NOS. All patients underwent 3.0 T MRI with 3D pCASL. Maximum tumor blood flow (maxTBF) and normalized TBF relative to white matter (nTBF WM) and gray matter (nTBF GM) were measured using approximately 30-mm² hotspot ROIs.
RESULTS: In gliomas, maxTBF, nTBF WM, and nTBF GM differentiated grade 2 from grade 3-4 tumors, with AUCs of 0.848, 0.833, and 0.84, respectively. The maxTBF threshold was 63.3 mL/100 g/min; AUCs were 0.743-0.768 for grade 2 versus grade 3 and 0.668-0.715 for grade 3 versus grade 4. After exclusion of NOS cases, glioblastomas and grade 4 astrocytomas did not differ significantly in maxTBF or nTBF (pfdr > 0.05). 3D pCASL also differentiated non-enhancing glioblastomas from grade 2 astrocytomas (maxTBF, pfdr = 0.0018; nTBF, pfdr = 0.0036-0.006), with AUCs of 0.78-0.86, a maxTBF cutoff of 64.1 mL/100 g/min, and specificity up to 96%. maxTBF and nTBF moderately correlated with Ki-67 (r = 0.44-0.50; pfdr < 0.001).
CONCLUSIONS: 3D pCASL provides high diagnostic accuracy for differentiating grade 2 gliomas from high-grade gliomas and grade 2 from grade 3 tumors within the WHO 2021 framework, while remaining fully non-invasive and requiring no contrast agent.
引用
- Batalov, Zakharova, Elagina, et al. Diagnostic value of 3D pCASL perfusion in glioma grading according to the WHO 2021 classification: a retrospective study of 530 cases. Neuroradiology. 2026. PMID: 42895656. doi:10.1007/s00234-026-04225-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。